Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 1
2013 1
2015 1
2016 2
2017 2
2019 1
2020 2
2021 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS, Sinha MS, Avorn J. Kesselheim AS, et al. JAMA Intern Med. 2017 Nov 1;177(11):1658-1664. doi: 10.1001/jamainternmed.2017.4329. JAMA Intern Med. 2017. PMID: 28892528 Review.
The high prices of brand-name prescription drugs are a growing source of controversy in the United States. ...Overall, most new drugs receive about 12 to 16 years of market exclusivity from both kinds of monopoly protection combine …
The high prices of brand-name prescription drugs are a growing source of controversy in the United States. ...Ov …
Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017.
Rome BN, Lee CC, Gagne JJ, Kesselheim AS. Rome BN, et al. Value Health. 2021 Jun;24(6):804-811. doi: 10.1016/j.jval.2020.12.020. Epub 2021 Apr 22. Value Health. 2021. PMID: 34119078 Free article.
OBJECTIVES: In the United States, brand-name prescription drugs remain expensive until market exclusivity ends and lower-cost generics become available. ...CONCLUSION: Early generic uptake decreased over the past several years. This trend …
OBJECTIVES: In the United States, brand-name prescription drugs remain expensive until market exclusiv
Beyond The High Prices Of Prescription Drugs: A Framework To Assess Costs, Resource Allocation, And Public Funding.
Darrow JJ, Light DW. Darrow JJ, et al. Health Aff (Millwood). 2021 Feb;40(2):281-288. doi: 10.1377/hlthaff.2020.00328. Health Aff (Millwood). 2021. PMID: 33523733
New exclusivities increase prices by delaying competition, and payment programs such as Medicare Part D help guarantee that prices will be paid no matter how high they rise. ...This article provides a more comprehensive framework for legislators and scholars to use in asse …
New exclusivities increase prices by delaying competition, and payment programs such as Medicare Part D help guarantee that prices wi …
The unexpected consequences of generic entry.
Castanheira M, Ornaghi C, Siotis G. Castanheira M, et al. J Health Econ. 2019 Dec;68:102243. doi: 10.1016/j.jhealeco.2019.102243. Epub 2019 Oct 1. J Health Econ. 2019. PMID: 31734583
Generic drugs are sold at a fraction of the original brand price. Yet, generic entry typically produces a drop in the quantity market share of the molecule losing exclusivity. This effect is economically and statistically significant for a large dataset cover …
Generic drugs are sold at a fraction of the original brand price. Yet, generic entry typically produces a drop in the quantity mar
Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL. Mendoza RL. J Med Econ. 2020 Sep;23(9):915-922. doi: 10.1080/13696998.2020.1772797. Epub 2020 Jun 25. J Med Econ. 2020. PMID: 32432950 Free article.
AIM: Prescription drug prices in the United States are considered rather extreme. ...FINDINGS: With certain qualifications, evidence confirms price inelasticity of prescription drugs and medical treatments, along with substitution effects from h …
AIM: Prescription drug prices in the United States are considered rather extreme. ...FINDINGS: With certain qualificati …
Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
Lin SY, Baumann K, Zhou C, Zhou W, Cuellar AE, Xue H. Lin SY, et al. JAMA Netw Open. 2021 Nov 1;4(11):e2135371. doi: 10.1001/jamanetworkopen.2021.35371. JAMA Netw Open. 2021. PMID: 34807258 Free PMC article.
Data were analyzed from November 1, 2020, to March 30, 2021. EXPOSURES: The market entry of 5 generic statin medications (atorvastatin, rosuvastatin, simvastatin, lovastatin, and pravastatin). ...The number of brand-name statin purchases decreased by 90.9% (95% CI, 56%-98% …
Data were analyzed from November 1, 2020, to March 30, 2021. EXPOSURES: The market entry of 5 generic statin medications (atorvastati …
Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis.
Rome BN, Kesselheim AS. Rome BN, et al. Clin Infect Dis. 2020 Oct 23;71(7):1671-1675. doi: 10.1093/cid/ciz1039. Clin Infect Dis. 2020. PMID: 31630159
In 2018, the REVAMP Act was proposed in Congress to reward manufacturers of certain novel antibiotics with transferrable market exclusivity vouchers. METHODS: We estimated the economic impact of this proposal by identifying antimicrobial drugs approved by the …
In 2018, the REVAMP Act was proposed in Congress to reward manufacturers of certain novel antibiotics with transferrable market ex
Continuing trends in U.S. brand-name and generic drug competition.
Grabowski H, Long G, Mortimer R, Bilginsoy M. Grabowski H, et al. J Med Econ. 2021 Jan-Dec;24(1):908-917. doi: 10.1080/13696998.2021.1952795. J Med Econ. 2021. PMID: 34253119 Free article.
OBJECTIVE: To provide updated evidence in a series of analyses of U.S. trends over the past two decades in key financial metrics for branded drugs: market exclusivity periods (MEPs, the time between launch and first generic entry) for new molecular entities ( …
OBJECTIVE: To provide updated evidence in a series of analyses of U.S. trends over the past two decades in key financial metrics for branded …
Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.
Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, Haddox DJ, Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya ID, O'Brien C, Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH. Smith SM, et al. Pain. 2013 Nov;154(11):2287-2296. doi: 10.1016/j.pain.2013.05.053. Epub 2013 Jun 20. Pain. 2013. PMID: 23792283 Free PMC article. Review.
As the nontherapeutic use of prescription medications escalates, serious associated consequences have also increased. This makes it essential to estimate misuse, abuse, and related events (MAREs) in the development and postmarketing adverse event surveillance and monitorin …
As the nontherapeutic use of prescription medications escalates, serious associated consequences have also increased. This makes it e …
The US orphan drug programme 1983-1995.
Shulman SR, Manocchia M. Shulman SR, et al. Pharmacoeconomics. 1997 Sep;12(3):312-26. doi: 10.2165/00019053-199712030-00004. Pharmacoeconomics. 1997. PMID: 10170457 Review.
Over the 13-year analysis period, the FDA granted 631 orphan designations involving 450 different drugs, for which 121 FDA marketing approvals have been granted. ...Even though the Prescription Drug User Fee Act of 1992 did not recognise orphan status …
Over the 13-year analysis period, the FDA granted 631 orphan designations involving 450 different drugs, for which 121 FDA …
15 results